Background: The prevalence of kidney involvement during SARS-CoV-2 infection has been reported to be high. Nevertheless, data are lacking about the determinants of acute kidney injury (AKI) and the combined effect of chronic kidney disease (CKD) and AKI in COVID-19 patients. Methods: We collected data on patient demographics, comorbidities, chronic medications, vital signs, baseline laboratory test results and in-hospital treatment in patients with COVID-19 consecutively admitted to our Institution. Chronic kidney disease was defined as eGFR < 60 mL/min per 1.73 m2 or proteinuria at urinalysis within 180 days prior to hospital admission. AKI was defined according to KDIGO criteria. The primary and secondary outcomes were the development of AKI and death. Results: Of 777 patients eligible for the study, acute kidney injury developed in 176 (22.6%). Of these, 79 (45%) showed an acute worsening of a preexisting CKD, and 21 (12%) required kidney replacement therapy. Independent associates of AKI were chronic kidney disease, C-reactive protein (CRP) and ventilation support. Among patients with acute kidney injury, 111 died (63%) and its occurrence increased the risk of death by 60% (HR 1.60 [95% IC 1.21–2.49] p = 0.002) independently of potential confounding factors including hypertension, preexisting kidney damage, and comorbidities. Patients with AKI showed a significantly higher rate of deaths attributed to bleeding compared to CKD and the whole population (7.5 vs 1.5 vs 3.5%, respectively). Conclusion: Awareness of kidney function, both preexisting CKD and development of acute kidney injury, may help to identify those patients at increased risk of death.

Kidney disease and all-cause mortality in patients with COVID-19 hospitalized in Genoa, Northern Italy

Esposito P.;Taramasso L.;Saio M.;Briano F.;Russo C.;Dettori S.;Vena A.;Di Biagio A.;Bassetti M.;Viazzi F.;De Maria A.;Di Biagio A.;Mikulska M.;Giacobbe D. R.;Balletto E.;Labate L.;Mirabella M.;Pincino R.;Sarteschi G.;Sepulcri C.;Tutino S.;Pontremoli R.;Beccati V.;Leoncini G.;Balestra A.;Bardi N.;Boccafogli R.;Cortese P.;Cuttone G.;Feltrin S.;Giovinazzo S.;Giuntini P.;Perazzo T.;Pescetelli F.;Sottano M.;Perazzo F.;Bovio M.;Vacca P.;Porto I.;La Malfa G.;Gil Ad V.;Pisciotta L.;Passalacqua G.;Bagnasco D.;Braido F.;Tagliabue E.;Giacomini M.;Mora S.
2021-01-01

Abstract

Background: The prevalence of kidney involvement during SARS-CoV-2 infection has been reported to be high. Nevertheless, data are lacking about the determinants of acute kidney injury (AKI) and the combined effect of chronic kidney disease (CKD) and AKI in COVID-19 patients. Methods: We collected data on patient demographics, comorbidities, chronic medications, vital signs, baseline laboratory test results and in-hospital treatment in patients with COVID-19 consecutively admitted to our Institution. Chronic kidney disease was defined as eGFR < 60 mL/min per 1.73 m2 or proteinuria at urinalysis within 180 days prior to hospital admission. AKI was defined according to KDIGO criteria. The primary and secondary outcomes were the development of AKI and death. Results: Of 777 patients eligible for the study, acute kidney injury developed in 176 (22.6%). Of these, 79 (45%) showed an acute worsening of a preexisting CKD, and 21 (12%) required kidney replacement therapy. Independent associates of AKI were chronic kidney disease, C-reactive protein (CRP) and ventilation support. Among patients with acute kidney injury, 111 died (63%) and its occurrence increased the risk of death by 60% (HR 1.60 [95% IC 1.21–2.49] p = 0.002) independently of potential confounding factors including hypertension, preexisting kidney damage, and comorbidities. Patients with AKI showed a significantly higher rate of deaths attributed to bleeding compared to CKD and the whole population (7.5 vs 1.5 vs 3.5%, respectively). Conclusion: Awareness of kidney function, both preexisting CKD and development of acute kidney injury, may help to identify those patients at increased risk of death.
File in questo prodotto:
File Dimensione Formato  
2020 JN AKI in COVID ER.pdf

accesso aperto

Descrizione: Articolo su rivista
Tipologia: Documento in Pre-print
Dimensione 913.98 kB
Formato Adobe PDF
913.98 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11567/1037223
Citazioni
  • ???jsp.display-item.citation.pmc??? 33
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 36
social impact